BioWorld

Jan. 28, 2008

View Archived Issues

Amgen Earnings Beat Estimates, But ESA Uncertainty Looms

Despite regulatory and reimbursement challenges to its erythropoietin stimulating agent (ESA) franchise, Amgen Inc. beat analyst estimates for earnings in the fourth quarter of 2007. (BioWorld Today) Read More

Nuvelo Still Seeking Efficacy of Thrombolytic Drug Alfimeprase

Read More

Research Firms Up Alzheimer's Connection to Blood Flow Issues

Read More

FDA Taking Proactive Approach in Detecting Psychiatric Effects

Read More

MiddleBrook to Raise $21M in Private Placement Offering

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Appointments And Advancements

Read More